Phillip Joseph Mertz
CIK: 0002028904
Associated companies
Transaction History
| ACOG | ▲ Buy | Grant | 7,241 | $0 | 1/14/2026 | View on chart |
| ACOG | ▼ Sell | Open Market | 27,778 | $250K | 8/18/2025 | View on chart |
| ACOG | ▲ Buy | Grant | 7,241 | $0 | 1/14/2026 | View on chart |
| ACOG | ▼ Sell | Open Market | 27,778 | $250K | 8/18/2025 | View on chart |
We use analytics to understand how market-wall is used. No personal data is sold.
AI Market Commentary
AI-generatedAll commentary →Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
October 1, 2026
Alpha Cognition Releases 180-Day Data on CONVERGE Program
Alpha Cognition has published results from a 180‑day study of its CONVERGE program. The data covers patients who are taking ZUNVEYL, donepezil, galantamine or rivastigmine. The release gives a clearer view of how the program performs in real‑world use. Investors can use the information to assess the company’s therapeutic strategy.
Alpha Cognition Releases 180-Day Data on CONVERGE Program. Alpha Cognition has published results from a 180‑day study of its CONVERGE program. The data covers patients who are taking ZUNVEYL, donepezil, galantamine or rivastigmine. The release gives a clearer view of how the program performs in real‑world use. Investors can use the information to assess the company’s therapeutic strategy.